Leukemia

Matt Kalaycio, MD, FACP, has been elected chair of National Comprehensive Cancer Network’s board of directors.

The results from a nationwide survey, published in JAMA Network Open, highlight the complex issues oncologists are grappling with in integrating artificial intelligence.

A novel bivalent-targeting, intrathecally delivered chimeric antigen receptor T-cell therapy decreased tumor size in patients with recurrent glioblastoma, according to results from a phase 1 study published in Nature Medicine.

The FDA granted accelerated approval to ponatinib with chemotherapy for the treatment of adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, according to a press release.

Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.

Patients with post-transplant relapsed B-cell acute lymphoblastic leukemia who received chimeric antigen receptor T-cell therapy had superior outcomes compared with alternative approaches, study results showed.

The FDA approved inotuzumab ozogamicin for use in pediatric patients with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia, according to a press release.

David J. Benjamin, MD, recently met with a patient who recalled the moment a previous physician had diagnosed him with cancer.

Cancer research and advocacy funding disproportionately skewed toward certain subtypes, leaving many cancers with high mortality rates and those affecting Black patients underfunded, study results in JCO Oncology Practice showed.

SAN DIEGO — Personalizing treatment using both geriatric assessment and genetic profiling may decrease rates of early mortality among older patients with acute myeloid leukemia, according to a study from ASH Annual Meeting and Exposition.